Targeting Src Family Kinases Inhibits Growth and Lymph Node Metastases of Prostate Cancer in an Orthotopic Nude Mouse Model
| Autor: | Juri G. Gelovani, Andrei Volgin, Kacy A. Phillips, Gary E. Gallick, Zhengxin Wang, Amer Najjar, John C. Araujo, Serk In Park, Jing Zhang, Sun Jin Kim |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
Cancer Research Dasatinib Mice Nude Antineoplastic Agents Metastasis Mice Prostate cancer Drug Delivery Systems Nude mouse Cell Movement LYN hemic and lymphatic diseases Tumor Cells Cultured medicine Animals Humans Cell Proliferation biology Kinase Prostatic Neoplasms Cancer medicine.disease biology.organism_classification Xenograft Model Antitumor Assays Tumor Burden Disease Models Animal Thiazoles Crk-Associated Substrate Protein Pyrimidines src-Family Kinases Oncology Focal Adhesion Kinase 1 Lymphatic Metastasis Cancer research Tyrosine medicine.drug Proto-oncogene tyrosine-protein kinase Src |
| Zdroj: | Cancer Research. 68:3323-3333 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | Aberrant expression and/or activity of members of the Src family of nonreceptor protein tyrosine kinases (SFK) are commonly observed in progressive stages of human tumors. In prostate cancer, two SFKs (Src and Lyn) have been specifically implicated in tumor growth and progression. However, there are no data in preclinical models demonstrating potential efficacy of Src inhibitors against prostate cancer growth and/or metastasis. In this study, we used the small molecule SFK/Abl kinase inhibitor dasatinib, currently in clinical trials for solid tumors, to examine in vitro and in vivo effects of inhibiting SFKs in prostate tumor cells. In vitro, dasatinib inhibits both Src and Lyn activity, resulting in decreased cellular proliferation, migration, and invasion. In orthotopic nude mouse models, dasatinib treatment effectively inhibits expression of activated SFKs, resulting in inhibition of both tumor growth and development of lymph node metastases in both androgen-sensitive and androgen-resistant tumors. In primary tumors, SFK inhibition leads to decreased cellular proliferation (determined by immunohistochemistry for proliferating cell nuclear antigen). In vitro, small interfering RNA (siRNA)–mediated inhibition of Lyn affects cellular proliferation; siRNA inhibition of Src affects primarily cellular migration. Therefore, we conclude that SFKs are promising therapeutic targets for treatment of human prostate cancer and that Src and Lyn activities affect different cellular functions required for prostate tumor growth and progression. [Cancer Res 2008;68(9):3323–33] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|